المؤلفون: Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mak GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Gurden MD; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Drosopoulos K; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Walsh K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Theofani E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Filosto S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Saville H; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. spiros.linardopoulos@icr.ac.uk.; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Oct; Vol. 18 (10), pp. 1696-1707.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Checkpoints*/drug effects, Pyrimidines/*pharmacology , Spindle Apparatus/*metabolism , Triazoles/*pharmacology , Triple Negative Breast Neoplasms/*pathology, Animals ; Biological Availability ; Cell Cycle/drug effects ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chromosome Segregation/drug effects ; Chromosomes, Human/genetics ; Drug Synergism ; Humans ; Mice ; PTEN Phosphohydrolase/metabolism ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein Serine-Threonine Kinases/metabolism ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/metabolism ; Pyrimidines/chemistry ; Spindle Apparatus/drug effects ; Triazoles/chemistry ; Triple Negative Breast Neoplasms/drug therapy

المؤلفون: Bajrami I; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Marlow R; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., van de Ven M; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Brough R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Pemberton HN; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Frankum J; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Song F; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Rafiq R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Konde A; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Krastev DB; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Menon M; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Campbell J; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Gulati A; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Kumar R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Pettitt SJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Gurden MD; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Cardenosa ML; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Biomedical Research Institute INCLIVA, Hospital Clinico Universitario Valencia, University of Valencia, Spain., Chong I; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Gazinska P; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., Wallberg F; FACS Core Facility, The Institute of Cancer Research, London, United Kingdom., Sawyer EJ; Division of Cancer Studies, Guy's Hospital, King's College London, London, United Kingdom., Martin LA; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Dowsett M; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Natrajan R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Ryan CJ; Systems Biology Ireland, University College Dublin, Dublin, Ireland., Derksen PWB; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jonkers J; Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Tutt ANJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., Ashworth A; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu., Lord CJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.

المصدر: Cancer discovery [Cancer Discov] 2018 Apr; Vol. 8 (4), pp. 498-515.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms/*drug therapy , Cadherins/*deficiency , Crizotinib/*pharmacology , Protein-Tyrosine Kinases/*antagonists & inhibitors , Proto-Oncogene Proteins/*antagonists & inhibitors, Anilides/pharmacology ; Anilides/therapeutic use ; Animals ; Antigens, CD/genetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/metabolism ; Cadherins/genetics ; Cell Line, Tumor ; Crizotinib/therapeutic use ; Female ; Humans ; Mice ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Quinolines/pharmacology ; Quinolines/therapeutic use

المؤلفون: Dolly SO; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Royal Marsden Hospital, London, UK., Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Drosopoulos K; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Clarke P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., de Bono J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Royal Marsden Hospital, London, UK., Kaye S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Royal Marsden Hospital, London, UK., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2017 Sep 26; Vol. 117 (7), pp. 954-964. Date of Electronic Publication: 2017 Aug 22.

نوع المنشور: Journal Article; Validation Study

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Proteins/*deficiency , Cell Cycle Proteins/*genetics , F-Box Proteins/*genetics , Intracellular Signaling Peptides and Proteins/*genetics , Mitosis/*genetics , Neoplasms/*genetics , Protein Serine-Threonine Kinases/*genetics , Ubiquitin-Protein Ligases/*deficiency , Ubiquitin-Protein Ligases/*genetics, Apoptosis/genetics ; Cell Cycle/genetics ; Cell Line, Tumor ; Clathrin/antagonists & inhibitors ; F-Box-WD Repeat-Containing Protein 7 ; Humans ; RNA Interference ; RNA, Small Interfering ; Sulfonamides/pharmacology ; Synthetic Lethal Mutations ; Thiazolidines/pharmacology

المؤلفون: Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Mak GWY; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Xavier CPR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., O'Fee L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., vanMontfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2017 Apr 25; Vol. 116 (9), pp. 1166-1176. Date of Electronic Publication: 2017 Mar 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Proteins/*genetics , Heterocyclic Compounds, 4 or More Rings/*administration & dosage , M Phase Cell Cycle Checkpoints/*drug effects , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*administration & dosage , Protein Serine-Threonine Kinases/*genetics , Protein-Tyrosine Kinases/*genetics, Animals ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Line, Tumor ; HCT116 Cells ; Humans ; Mice ; Neoplasms/genetics ; Neoplasms/pathology ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Xenograft Model Antitumor Assays

المؤلفون: Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom., Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Present address: Phenex Pharmaceuticals, Ludwigshafen am Rhein, Germany., Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Present address: Lahore University of Management Sciences, D.H.A. Lahore Cantt, Lahore, Pakistan., Linardopoulos S; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

المصدر: Oncotarget [Oncotarget] 2016 Jul 18; Vol. 9 (28), pp. 19525-19542. Date of Electronic Publication: 2016 Jul 18 (Print Publication: 2018).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE

المؤلفون: Gurden MD; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Division of Structural Biology, The Institute of Cancer Research, London, United Kingdom., Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Cheung KM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., McAndrew C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Wood A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Boxall K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mak G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Van Montfort RL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Division of Structural Biology, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom. Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Spiros.Linardopoulos@icr.ac.uk.

المصدر: Cancer research [Cancer Res] 2015 Aug 15; Vol. 75 (16), pp. 3340-54. Date of Electronic Publication: 2015 Jul 22.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Point Mutation*, Cell Cycle Proteins/*genetics , Drug Resistance, Neoplasm/*genetics , Protein Kinase Inhibitors/*pharmacology , Protein Serine-Threonine Kinases/*genetics , Protein-Tyrosine Kinases/*genetics, Aniline Compounds/chemistry ; Aniline Compounds/metabolism ; Aniline Compounds/pharmacology ; Cell Cycle Proteins/chemistry ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/genetics ; Dose-Response Relationship, Drug ; ErbB Receptors/antagonists & inhibitors ; Gefitinib ; HCT116 Cells ; HEK293 Cells ; Heterocyclic Compounds, 2-Ring/chemistry ; Heterocyclic Compounds, 2-Ring/metabolism ; Heterocyclic Compounds, 2-Ring/pharmacology ; Humans ; Models, Molecular ; Molecular Structure ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplasms/pathology ; Protein Binding ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/metabolism ; Protein Serine-Threonine Kinases/chemistry ; Protein Serine-Threonine Kinases/metabolism ; Protein Structure, Tertiary ; Protein-Tyrosine Kinases/chemistry ; Protein-Tyrosine Kinases/metabolism ; Pyrazoles/chemistry ; Pyrazoles/metabolism ; Pyrazoles/pharmacology ; Quinazolines/chemistry ; Quinazolines/metabolism ; Quinazolines/pharmacology

المؤلفون: Westhorpe FG; University of Manchester, UK., Diez MA, Gurden MD, Tighe A, Taylor SS

المصدر: Chromosoma [Chromosoma] 2010 Aug; Vol. 119 (4), pp. 371-9. Date of Electronic Publication: 2010 Feb 17.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Austria NLM ID: 2985138R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0886 (Electronic) Linking ISSN: 00095915 NLM ISO Abbreviation: Chromosoma Subsets: MEDLINE

مواضيع طبية MeSH: Gene Expression* , Mitosis*, Cell Cycle Proteins/*metabolism , MAP Kinase Kinase Kinases/*metabolism , Spindle Apparatus/*metabolism, Anaphase ; Calcium-Binding Proteins/metabolism ; Cdc20 Proteins ; Cell Cycle Proteins/genetics ; Chromosomes, Human/genetics ; Chromosomes, Human/metabolism ; HeLa Cells ; Humans ; Kinetochores/metabolism ; Mad2 Proteins ; Protein Kinases/genetics ; Protein Kinases/metabolism ; Protein Serine-Threonine Kinases/metabolism ; RNA Interference ; RNA, Small Interfering/genetics ; Repressor Proteins/metabolism ; Spindle Apparatus/genetics

المؤلفون: Gurden MD; Faculty of Life Sciences, Michael Smith Building, University of Manchester, Manchester M13 9PT, UK., Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, Spielmann HP, Malumbres M, Wolthuis RM, Cleveland DW, Taylor SS

المصدر: Journal of cell science [J Cell Sci] 2010 Feb 01; Vol. 123 (Pt 3), pp. 321-30. Date of Electronic Publication: 2010 Jan 05.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Company of Biologists Country of Publication: England NLM ID: 0052457 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-9137 (Electronic) Linking ISSN: 00219533 NLM ISO Abbreviation: J Cell Sci Subsets: MEDLINE

مواضيع طبية MeSH: Cell Cycle Proteins/*metabolism , Chromosomal Proteins, Non-Histone/*metabolism , Microfilament Proteins/*metabolism, Anaphase-Promoting Complex-Cyclosome ; Animals ; Antigens, CD ; Cadherins/genetics ; Cadherins/metabolism ; Cdc20 Proteins ; Cdh1 Proteins ; Cell Cycle Proteins/genetics ; Cell Line, Tumor ; Cells, Cultured ; Humans ; Kinetochores/metabolism ; Mice ; Microscopy ; Prenylation ; RNA Interference ; Ubiquitin-Protein Ligase Complexes/metabolism